Rezolute, Inc. (RZLT )

Currency in USD Disclaimer
$4.01 +$0.04 (0.88%)
Open 04/24/2025
$4
$4.27
$2.22
$6.19

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol RZLT
  • Company Rezolute, Inc.
  • Price $4.01
  • Changes Percentage 0.88
  • Change 0.035
  • Day Low $4
  • Day High $4.27
  • Year High $6.19
  • Year Low $2.22
  • Market Cap $247,589,880
  • Price Avg 50 EMA (D) $3.54
  • Price Avg 200 EMA (D) $4.53
  • Exchange NASDAQ
  • Volume 354,237
  • Average Volume 599,723
  • Open $4.01
  • Previous Close $3.97
  • EPS -1.23
  • PE -3.33
  • Earnings Announcement 2025-05-13 10:59:00
  • Shares Outstanding $60,535,423

Company brief: REZOLUTE, INC. (RZLT )

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

RZLT Corporation News

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

April 23, 2025 at 12:05 pm ET

globenewswire.com -- NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative t...

Income Statement